During an “intense” time of year for Seqirus—as characterized by the CSL unit’s president Gordon Naylor—the company can take a moment to appreciate that, after three years, it has swung ...

With the former Novartis ($NVS) flu vaccine unit in hand, CSL has big plans for its newly formed Seqirus unit. But it’ll be a bumpy path toward reaching its goals ...

Revenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant fall in immunisation rates, particularly in the US. CSL Seqirus brought in ...